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Abstract
We examined the role of endogenous dopamine (DA) in regulating the number of intrinsic tyrosine hydroxylase-positive
(TH+) striatal neurons using mice at postnatal day (PND) 4 to 8, a period that corresponds to the developmental peak in the
number of these neurons. We adopted the strategy of depleting endogenous DA by a 2-day treatment with a-methyl-p-
tyrosine (aMpT, 150 mg/kg, i.p.). This treatment markedly increased the number of striatal TH+ neurons, assessed by
stereological counting, and the increase was highly correlated to the extent of DA loss. Interestingly, TH+ neurons were
found closer to the clusters of DA fibers after DA depletion, indicating that the concentration gradient of extracellular DA
critically regulates the distribution of striatal TH+ neurons. A single i.p. injection of the D1 receptor antagonist, SCH23390
(0.1 mg/kg), the D2/D3 receptor antagonist, raclopride (0.1 mg/kg), or the D4 receptor antagonist, L-745,870 (5 mg/kg) in
mice at PND4 also increased the number of TH+ neurons after 4 days. Treatment with the D1-like receptor agonist SKF38393
(10 mg/kg) or with the D2-like receptor agonist, quinpirole (1 mg/kg) did not change the number of TH+ neurons. At least
the effects of SCH23390 were prevented by a combined treatment with SKF38393. Immunohistochemical analysis indicated
that striatal TH+ neurons expressed D2 and D4 receptors, but not D1 receptors. Moreover, treatment with the a4b2 receptor
antagonist dihydro-b-erythroidine (DHbE) (3.2 mg/kg) also increased the number of TH+ neurons. The evidence that DHbE
mimicked the action of SCH23390 in increasing the number of TH+ neurons supports the hypothesis that activation of D1
receptors controls the number of striatal TH+ neurons by enhancing the release of acetylcholine. These data demonstrate
for the first time that endogenous DA negatively regulates the number of striatal TH+ neurons by direct and indirect
mechanisms mediated by multiple DA receptor subtypes.
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Introduction
Tyrosine hydroxylase (TH)-expressing medium sized aspiny
neurons are present in the adult striatum of rodents, monkeys, and
humans [1–8]. These neurons stain for the high affinity dopamine
(DA) transporter [6,9], and for the GABA-synthesizing enzyme,
glutamate decarboxylase (GAD) [3,9]. In addition, intrinsic TH+-
neurons of the human striatum express Nurr1, a putative
specification factor of mesencephalic DAergic neurons [5]. The
number of TH+-neurons in the adult neostriatum varies consid-
erably in different species, being extremely low in rats and mice
(only 10–15 cells in the entire striatum) and high in monkeys
(between tens to hundreds of thousands) [1,2,6]. What makes these
cells potentially relevant to human pathology is their reactivity to
DAergic denervation. Chemical lesions of the nigro-striatal
DAergic pathway increase the number of striatal TH+-neurons
in rodents and monkeys [2,3,6,9,10]. In addition, an increased
density of TH+ neurons in autoptic striatal samples from patients
with Parkinson’s disease (PD) has been reported by Porritt et al.
[11], but not by Huot et al. [12]. In the latter study, however, all
patients had been treated with the DA precursor, L-39,59-
dihydroxyphenylalanine (L-DOPA) [12]. Remarkably, the num-
ber of TH+-neurons was reduced in the striatum of individuals
affected by Huntington’s chorea [12], in which DA concentrations
are elevated [13,14]. These findings suggest that DAergic
innervation produces a negative signal that restrains the number
of intrinsic striatal TH+-neurons [8]. Whether this signal
corresponds to DA itself or to other factors that affect cell
differentiation or survival is unknown at present.
We have found [15] that the number of intrinsic striatal TH+
neurons is elevated in mice during early postnatal life with a peak
of 6,000–8,000 cells/hemistriatum at postnatal day (PND) 8, when
afferent DAergic axons are scarce and heterogeneously distributed
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as compared to adult striatum. These DAergic axons are observed
as ‘‘clusters’’ of DA fibers scattered in the striatum, which produce
dense aggregates, defined as ‘‘DA islands’’ [16,17].
At this age, striatal TH+ neurons are found at a relatively long
distance (about 50 mm) from clusters of DAergic fibers [15]. The
number of TH+ neurons sharply decreases at PND16 along with
the increase in DAergic innervation [15]. We used PND4-PND8
mice as a model to examine the role of endogenous DA in the
regulation of striatal TH+ neurons. We adopted the strategy of
depleting endogenous DA without affecting the anatomical
integrity of the nigro-striatal DAergic pathway, or, alternatively,
blocking the action of endogenous DA with the use of subtype-
selective DA receptor antagonists.
Results
Increased number of striatal TH+ neurons following
dopamine depletion
TH+ neurons in the mouse striatum were identified by
immunohistochemistry as rounded medium-sized aspiny neurons
with a diameter of the cell body of 662.3 mm (means+S.E.M;
n= 18). These cells account for 3.9760.21% of the whole striatal
NeuN+ neuronal population, at PND8. Double fluorescent
staining showed that TH+ cells stained for the high affinity DA
transporter, DAT, which is a selective marker of DAergic neurons,
but do not stain for aromatic amino acid decarboxylase (AADC),
the enzyme that converts L-3,5,-dihydroxyphenylalanine (L-
DOPA) into DA (Fig. 1).
We carried out double fluorescent immunohistochemistry to
determine whether TH colocalized with GAD (a marker of
GABAergic neurons), dynorphin (a marker of striatal projection
neurons of the ‘‘direct pathway’’), enkephalin (a marker of striatal
projection neurons of the ‘‘indirect pathway’’), or choline
acetyltransferase (ChAT) (a marker of cholinergic interneurons).
TH+ cells were immunoreactive for GAD, dynorphin and
enkephalins, but nor for ChAT (Fig. 2).
Stereological counting confirmed the developmental peak in the
number of striatal TH+-neurons at PND8 (total number of TH+
neurons per hemistriatum: 1,5346321 at PND1; 3,5776199 at
PND4; 4,7896406 at PND6; 6,0166701 at PND8; 1,7116296 at
PND14; means 6 S.E.M.; n = 6). PND4 mice were treated with
the specific TH inhibitor, aMpT (150 mg/kg, i.p., injected twice
with 24 h of interval). Mice were killed at PND6 or PND8 (i.e. 24
or 72 h after the last aMpT injection) for measurements of striatal
DA levels in left hemistriatum and cell counting in the right
hemistriatum. This allowed a correlation analysis between DA
levels and the number of TH+ neurons. Treatment with aMpT led
to a 71.6% reduction in striatal DA levels after 24 h (PND6),
followed by a partial recovery (47.5% reduction in DA levels) at
72 h (PND8), as compared to control mice treated with saline
(Fig. 3A). Stereological cell counting showed an increased number
of striatal TH+ neurons in aMpT-treated mice. Cell number
increased by two fold at 24 h, and by about 38% at 72 h after
aMpT injection (Fig. 3B). We found a high correlation between
DA loss and the number of TH+ neurons (r2 = 0.65; p,0.05) when
we pooled all data obtained in mice treated with saline or aMpT
and killed at PND6 and PND8 (Fig. 3C).
Changes in the anatomical distribution of striatal TH+
neurons in response to DA depletion
During the first postnatal week striatal striosomes are identified
by TH-immunoreactive islands and the surrounding tissue is
identified as ‘‘matrix’’ [18]. Dopamine (DA) axons in the
developing striatum are scarce and scattered when compared
with the adult striatum. During the first postnatal week one can
observe dense ‘‘clusters’’ of DA axons scattered in the striatum,
which produce a patchy image of mesostriatal TH+ nerve endings
(16,17). Our data showed that treatment with aMpT substantially
Figure 1. Phenotypic characterization of intrinsic TH+ neurons. Double fluorescence staining for TH and DAT, or AADC and for TH and BrdU
are shown in (A) and in (B), respectively. Co-localization was examined by densitometric analysis of red and green fluorescence in a selected region
corresponding to the horizontal line in the right panels. The coincidence of the fluorescence peaks is indicative of a high level of co-localization.
doi:10.1371/journal.pone.0044025.g001
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changes the anatomical distribution of TH+ neurons with respect
to the cluster of fibers. In control mice treated with saline at PND4
and killed at PND6, most TH+ neurons were found at a distance of
60 mm from clusters of TH+ fibers, calculated as the average of
three segments connecting the cell body of TH+ neurons to the
central portion and the peripheral borders of the clusters,
respectively (Fig. 4A). This distribution pattern is similar to that
already seen in untreated mice at PND8 [15] and reveals that the
localization of TH+ neurons is at the level of the matrix. Mice
treated twice with aMpT and killed at PND6 showed clusters of
DAergic fibers (‘‘DA islands’’) similarly to control mice. However,
the distribution of TH+ neurons changed dramatically in these
mice, with the majority of cells being detected in the close
proximity of DAergic fibers (Fig. 4A). Remarkably, 33.8364.89%
of TH+ neurons were found inside the clusters in mice treated with
aMpT vs. 17.3662.51% only in mice treated saline (see values
corresponding to ‘‘0’’ in the x-axis of Fig. 4A). We wish to
highlight that the real number of TH+ neurons found at relatively
long distance from DA clusters (20–60 mm) did not differ
substantially between mice treated with saline and aMpT
(3,1956261 and 3,6106184, respectively; n = 10), suggesting that
the increased number of TH+ neurons in the close proximity of
DAergic fibers fully accounts for the difference between saline and
aMpT. All TH+ neurons stained for GAD, but not ChAT, in both
controls and aMpT-treated mice (Fig. 4B,C). In addition, TH+
cells found in the close proximity of DAergic fibers in aMpT-
treated mice did not colocalize with Ki67 and did not incorporate
BrdU, suggesting that these cells are postmitotic and did not derive
from an increased proliferation of local neuroprogenitors
(Fig. 4D,E).
Systemic treatment with DA receptor antagonists
increased the number of striatal TH+ neurons
PND4 mice received a single i.p. injection with the following
DA receptor ligands: the D1 receptor antagonist, SCH23390
(0.1 mg/kg); the D1 receptor agonist, SKF38393 (10 mg/kg); the
mixed D2/D3 receptor antagonist, raclopride (0.1 mg/kg); the
Figure 2. Double fluorescence staining for TH and ChAT, GAD, ENK or DYN. Co-localization was examined by densitometric analysis of red
and green fluorescence in a selected region corresponding to the horizontal line in the right panels. The coincidence of the fluorescence peaks is
indicative of a high level of co-localization.
doi:10.1371/journal.pone.0044025.g002
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D2-like receptor agonist, quinpirole (1 mg/kg); or the selective D4
receptor antagonist, L-745,870 (5 mg/kg). SCH23390 and
raclopride were also injected in combination with SKF38393
and quinpirole, respectively. Mice were killed 4 days later, at
PND8. All antagonists injected alone significantly increased the
number of TH+ neurons in the striatum. The number of TH+
neurons increased by 81.4% with SCH23390 (F = 11.41; One-way
ANOVA+Bonferroni’s test, p,0.05; n= 12); 72% with raclopride
(F = 6.21; p,0.05; n = 17) or 120% with L-745,870 (p,0.05;
Student’s t test, n = 12) (Fig. 5A,B,C). Additional groups of PND4
mice (n = 6) received a single i.p. injection of saline, SCH23390
(0.1 mg/kg), the a4b2 receptor antagonist dihydro-b-erythroidine
(DHbE) (3.2 mg/kg) or SCH23390 plus DHbE. The number of
TH+ neurons increased by 56.24% with SCH23390, by 63.86%
with DHbE, and by 57.58% with SCH23390 plus DHbE
(F= 9.886; One-way ANOVA+Bonferroni’s test, p,0.05; n= 6)
(Fig. 5D). Treatment with SKF38393 or quinpirole did not change
the number of TH+ neurons either when injected in saline-treated
mice either when injected in mice subjected to striatal DA
depletion by aMpT treatment (Fig. 5A,B,E). In the groups of mice
treated with D1 receptor ligands, values obtained with SCH23390
alone were significantly different from values obtained with
SKF38393 alone or with SKF38393+SCH23390 (p,0.05). The
number of TH+ neurons did not differ among the groups treated
with saline, SKF38393 alone, or SKF38393+SCH23390 (Fig. 5A).
In the groups of mice treated with D2 receptor ligands, values
obtained with raclopride alone were significantly different from
values obtained with quinpirole alone (p,0.05), but not with
values obtained with raclopride+quinpirole (although raclopride
alone increased the number of TH+ neurons by 72% vs. saline, and
raclopride+quinpirole increased the number of TH+ neurons by
45% vs. saline and 18% vs. quinpirole alone). The number of TH+
neurons did not differ among the groups treated with saline,
quinpirole alone, or quinpirole+raclopride (Fig. 5B).
Immunohistochemical analysis of DA receptors in the
striatum
The localization of DA receptor subtypes in striatal TH+
neurons was examined in the striatum of PND4 and PND8 mice
by double fluorescent staining. At both ages, TH+ neurons stained
for D2 and D4 receptors. In contrast, D1 receptors were never
found in TH+ neurons (Fig. 6A).
No immunoreactivity for D1 and D2 dopamine receptors was
found in striatal sections of D1 and D2 receptor knockout mice,
respectively, which indicates a high specificity of immunostaining
(Fig. 6B).
Discussion
Chemical lesions with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine or 6-hydroxydopamine increase the number of striatal TH+
neurons in rodents and primates, suggesting that either DA or
other factors released from nigro-striatal dopaminergic fibers
restrain the number of intrinsic TH+ neurons in the striatum [8].
We decided to examine the role of endogenous DA in controlling
the number of intrinsic TH+ neurons using developing mice (for a
detailed characterization of the developmental profile of striatal
TH+ neurons in mice, see [15]). Striatal TH+ cells in mice at
PND6–8 expressed DAT, which is a specific marker of DAergic
neurons, but did not express AADC, the enzyme necessary for the
conversion of L-DOPA into DA. Striatal TH+ cells in adult mice
treated with 6-hydroxydopamine or methamphetamine were also
found to be devoid of AADC [10]. Thus, intrinsic striatal TH+
cells in both developing and adult mice may lack the ability to
synthesize DA, but they are a potential source for L-DOPA that
can be converted into DA by neighbor cells. Intrinsic striatal TH+
cells of developing mice were also immunoreactive for the GABA-
synthesizing enzyme, GAD, but not for the acetylcholine-
synthesizing enzyme, ChAT.
In the striatum, GAD is normally expressed by different
populations of interneurons as well as by medium spiny projection
neurons of the ‘‘direct’’ and ‘‘indirect’’ pathways [19]. TH+ cells
were immunoreactive for enkephalin and dynorphins, which are
peptide markers for projection neurons of the indirect and direct
pathway, respectively [20]. TH+ cells apparently expressed D2
receptors (which are normally expressed by projection neurons of
the indirect pathway), but not D1 receptors (which are normally
expressed by projection neurons of the direct pathway). This
particular profile is in agreement with the suggestion that TH+
neurons in the developing mouse striatum closely resemble
medium spiny projection neurons, but constitute a cell type
distinct from classical medium spiny neurons [21].
To elucidate the role of DA in this mechanism, we adopted the
strategy of leaving the innervation intact, and depleting endogenous
Figure 3. DA depletion increases the number of intrinsic TH+ neurons. DA levels and the number of TH+ neurons in the striatum of mice
treated with aMpT (150 mg/kg, i.p.; injected twice with 24 h of interval at PND4 and PND5), and killed 24 h (PND6) or 72 h (PND8) later are shown in
(D) and (E). Values are means+S.E.M. of 10 mice for group. *p,0.05 (Student’s test) vs. saline-treated mice. Correlation analysis between DA levels and
the number of TH+ neurons in shown in (F) (r2 = 0.65; p,0.05). Empty circles =mice treated with saline and killed at PND6; filled circles =mice treated
with aMpT and killed at PND6; empty squares =mice treated with saline and killed at PND8; filled squares =mice treated with aMpT and killed at
PND8.
doi:10.1371/journal.pone.0044025.g003
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DA with aMpT. We treated mice with aMpT at PND4 and PND5,
just prior to the developmental peak in the number of striatal TH+
neurons. DA is present in the mouse striatum at birth [22], but no
DA release can be detected by microdialysis before PND5 [23].
Thus, we inhibited DA synthesis in a time window that corresponds
to the first exposure of the striatal microenvironment to extracellular
DA. We found a strong effect of DA depletion on the number of
striatal TH+ neurons with a highly significant correlation between
the extent of DA loss and the increase in TH+ neurons. Remarkably,
DA loss caused a dramatic change in the distribution of TH+
neurons, with most of the newly formed TH+ neurons being placed
at short distance from DA islands. Our data suggest that DA
negatively regulates the number of TH+ neurons, and that the
distribution of TH+ neurons is determined by the concentration
gradient of extracellular DA in the developing striatum. It can be
argued that in response to DA depletion the majority of TH+ cells
should still be localized far from DA islands, i.e. at a ‘‘safety
distance’’ from the DA that is still produced by, and released from,
DAergic fibers. It is possible that the differentiation and spatial
distribution of TH+ cells is regulated by trophic/attractive signals
produced by DAergic fibers and, at the very opposite, by the
inhibitory action of DA, which restrains the number of TH+ cells in
Figure 4. DA depletion changes the spatial distribution of striatal TH+ neurons. The distribution profile of TH+ neurons in the striatum of
mice treated with saline or in striatum of mice treated with saline or aMpT at PND4 (2 injections 24 h apart) and killed at PND6 is shown in (A).
Representative images of neurons and fibers stained for TH are shown below the graph. The figure shows the triple vectors used for distance
determination. Segments connecting the cell body of TH+ neurons to the central border and the two peripheral borders of the clusters are indicated).
Note that most of the TH+ neurons are placed at shorter distance from the clusters of DA fibers in mice treated with aMpT. Double fluorescence
immunostaining for TH and GAD, ChAT, Ki-67, and BrdU in mice treated with saline or aMpT as above is shown in (B), (C), (D), and (E), respectively.
doi:10.1371/journal.pone.0044025.g004
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the vicinity of DAergic fibers. Perhaps, when DA levels are reduced
in response to aMpT, the unopposed action of these hypothetical
trophic signals will substantially increase the number of TH+ cells in
the vicinity of DAergic fibers, whereas in normal mice they can only
support differentiation of TH+ cells if concentrations of endogenous
DA fall below a critical threshold, i.e. far from the DA islands. This
hypothesis is line with two observations: (i) TH+ cells are barely
detectable before PND4, when the number of DA fibers afferent to
the striatum is low [15]; and (ii) in the adult striatum the number of
TH+ cells increases in response to partial DAergic denervation,
whereas TH+ cells are no longer detectable in response to a total
DAergic denervation [11].
Pharmacological experiments suggested that DA lowers the
number of striatal TH+ neurons acting at multiple DA receptor
subtypes. Drugs that block D1, D2/D3, or D4 receptors all
increased the number of TH+ neurons, thus mimicking the effects
of DA loss. Interestingly, TH+ neurons expressed D2 and D4, but
not D1 receptors. D2 and D4 receptors are both coupled to Gi
proteins [24] and, therefore, a Gi-dependent signaling pathway
activated by endogenous DA might restrain TH expression in
striatal interneurons. The indirect mechanism whereby endoge-
nous activation of D1 receptors negatively regulates the number of
TH+ neurons remains to be determined. D1 receptors are
localized on striatal cholinergic interneurons, where they facilitate
acetylcholine release [25–27]. Acetylcholine, in turn, facilitates DA
release via the activation of presynaptic nicotinic receptors [28].
An interesting possibility is that activation of D1 receptors controls
the number of striatal TH+ neurons by enhancing the release of
acetylcholine, which in turn facilitates DA release from nigro-
striatal terminals. The evidence that the nicotinic receptor
antagonist, DHbE, mimicked the action of SCH23390 in
increasing the number of TH+ neurons supports this hypothesis.
The pharmacological specificity of the effects we have seen with
DA receptors antagonists was supported by the use SKF38393 and
quinpirole, which activate D1-like and D2-like DA receptors,
respectively. SKF38393 had no effect on its own and reversed the
increase in the number of TH+ neurons induced by SCH23390.
Mice treated with raclopride+quinpirole showed a trend to a
reduction in the number of TH+ neurons as compared to mice
treated with raclopride alone, although the difference was not
statistically significant. The lack of activity of the two agonists
alone was unexpected if one assumes that these drugs may diffuse
to striatal TH+ neurons that are at ‘‘safe distance’’ from
endogenous DA. We speculate that activation of DA receptors is
necessary, but not sufficient, to negatively regulate the number of
striatal TH+ neurons. Peptides secreted by nigro-striatal dopami-
nergic fibers, such as cholecystokinin [29], might have a permissive
role in regulating the number of TH+ neurons.
The cellular processes that lead to the increased number of
striatal TH+ cells in response to DA loss is unknown. TH+ cells did
not express the mitotic marker, Ki-67, and did not incorporate
BrdU in both control mice and mice treated with aMpT. In
Figure 5. DA and receptors blockade increases the number of striatal TH+ neurons. Mice received a single i.p. injection with DA receptor
ligands or with a selective nicotinic acetylcholine a4b2 receptor antagonist dihydro-b-erythroidine (DHbE) at PND4 and were killed at PND8.
SKF = SKF38393 (10 mg/kg); SCH= SCH23390 (0.1 mg/kg); Q =quinpirole (0.1 mg/kg); RAC= raclopride (1 mg/kg); DHbE = dihydro-b-erythroidine
(3.2 mg/kg). (E) PND4 mice subjected to striatal DA depletion by treatment with the TH inhibitor aMpT (150 mg/kg, i.p., twice, with 24 h of interval)
were treated with quinpirole (0.1 mg/kg); (n = 6) or SKF38393 (10 mg/kg); (n = 6). Values are means+S.E.M. of 12 (A,C), 17 (B) or 6 (D,E) mice for group.
In (A), *p,0.05 (One-way ANOVA+Bonferroni’s test) vs. all other values; in (B), *p,0.05 (One-way ANOVA+Bonferroni’s test) vs. values obtained in
mice treated with saline or quinpirole alone; in (C,D,E), *p,0.05 (Student’s t test) vs. values obtained in mice treated with saline.
doi:10.1371/journal.pone.0044025.g005
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addition, TH+ cells of mice treated with aMpT behaved similarly
to TH+ cells of control mice in expressing the GABAergic marker,
GAD. This suggests three potential mechanisms responsible for
the increased number of TH+ cells in response to DA depletion: (i)
the induction of TH in a subpopulation of medium-spiny like
GABAergic neurons; (ii) the differentiation of post-mitotic
progenitor cells into double TH+/GAD+ neurons; and or (iii) an
increased survival of TH+/GAD+ neurons that are normally
eliminated by the action of extracellular DA between PND4 and
PND8. At least in monkeys, new striatal neurons are generated de
novo throughout the entire lifespan [30], but none of these neurons
develop a TH+ phenotype even in response to brain-derived
neurotrophic factor [31]. Thus, we favor the hypothesis that DA
loss or DA receptor blockade de-repress TH expression in a
subpopulation of developing GABAergic neurons bearing some of
the biochemical features of striatal projection neurons. cAMP
enhances TH expression acting at both transcriptional and
translational level [32–34], suggesting that activation of D2 or
D4 receptors by endogenous DA may restrain TH expression by
inhibiting cAMP formation. Activation of DA receptors might also
affect epigenetic mechanisms that critically regulate TH gene
expression [35,36]. Accordingly, D2 receptor blockade has been
shown to rapidly enhance H3 histone acetylation and phosphor-
ylation in the striatum [37].
In conclusion, our data show for the first time that the number
of striatal TH+ neurons is negatively regulated by endogenous DA
acting at multiple DA receptor subtypes. In addition, the
demonstration that TH+ neurons express D2-like receptors
suggests that DA might directly affect the fate of these neurons
perhaps regulating TH expression through epigenetic mecha-
nisms. Unraveling these mechanisms might provide new targets for
treatments aimed at implementing the number of striatal DAergic
cells in PD and other neurodegenerative disorders of the basal
ganglia. Whether pharmacological regulation of TH+ neurons in
the early postnatal life influences the plasticity of the adult striatum
in response to nigro-striatal denervation is an interesting question
that warrants further investigation.
Materials and Methods
Material
a-Methyl-p-tyrosine (aMpT) and 5-bromo-2-deoxyuridine
(BrdU) were purchased from Sigma (St. Louis, MO). SKF38393,
SCH23390, quinpirole, raclopride, L-745,870 and dihydro-b-
erythroidine were purchased from Tocris Bioscience (Bristol, UK).
Ethics Statement
This study (Ricerca Corrente 2010 ‘‘Modulation of striatal
plasticity’’ to IRCCS Neuromed Institute) was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Italian Institute of
Health. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the IRCCS Neuromed Institute.
Permit Number 432007/A was issued by the Italian Ministry of
Health. All efforts were made to minimize suffering. Animals were
treated i.p. with drugs and killed by decapitation at different times
after treatment.
Animals
Experiments were performed using CD1 mice (Charles River,
Calco, CO, Italy). All mice were kept under environmentally
controlled conditions (room temperature = 22uC, humidity = 40%)
on a 12-h light/dark cycle with food and water ad libitum.
Experimental design
Striatal DA depletion was induced in PND4 mice by systemic
injection of aMpT (150 mg/kg, i.p., twice, with 24 h of interval).
Control mice were injected with saline. Mice were killed by
Figure 6. Striatal TH+ neurons express D2 and D4 receptors. (A)
Double fluorescence staining for TH and D1, D2 or D4 receptors in the
striatum of mice at PND4 and PND8 is shown. Co-localization was
examined by densitometric analysis of red and green fluorescence in a
selected region corresponding to the horizontal line in the right panels.
The coincidence of the fluorescence peaks is indicative of a high level of
co-localization. (B) Immunoreactivity for D1 and D2 dopamine receptors
in striatal sections of adult wild-type and D1 or D2 receptor knockout
mice, respectively.
doi:10.1371/journal.pone.0044025.g006
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decapitation 24 or 72 h after the last injection of aMpT (n= 10) or
saline (n = 10) (i.e. at PND6 or PND8). Other groups of PND4
mice (n = 12) received a single i.p. injection of saline or one of the
following DA receptor ligands: SKF38393 (10 mg/kg), SCH23390
(0.1 mg/kg), quinpirole (1 mg/kg), raclopride (0.1 mg/kg) or L-
745,870 (5 mg/kg), SKF38393 plus SCH23390, or quinpirole plus
raclopride. In order to test the efficacy of DA agonists in a context
where D1 or D2 agonists may be competing with endogenous DA,
we treated PND4 mice with aMpT plus quinpirole (n = 6) or
aMpT plus SKF38393 (n= 6). In a second experiment, 5 mice per
group were treated with saline, quinpirole (1 mg/kg), raclopride
(0.1 mg/kg), and quinpirole+raclopride. These data were com-
bined with data obtained in the first experiment, as shown in
Fig. 3B). Finally, additional groups of PND4 mice (n = 6) received
a single i.p. injection of saline, SCH23390 (0.1 mg/kg), the
competitive a4b2 receptor antagonist dihydro-b-erythroidine
(DHbE) (3.2 mg/kg) or SCH23390 plus DHbE. All mice were
killed by decapitation four days after drug injections (i.e. at PND8).
Bromodeoxyuridine labeling
Mice were systemically injected with saline or aMpT (150 mg/
kg, i.p., twice, with 24 h of interval) at PND4 and PND5. The
same mice were injected with 3 injections of BrdU (50 mg/kg, i.p.,
every 2 h) at PND5. Mice were killed 24 h after the last BrdU
injection (PND6).
Monoamine assay
The striatum was homogenized by sonication in 0.6 ml of ice-
cold 0.1 M PCA, and DA levels were measured by HPLC with
electrochemical detection as described previously [38].
Immunohistochemical analysis
Brains were dissected out, fixed in ethanol (60%), acetic acid
(10%), and chloroform (30%), and included in paraffin. Tissue
sections (10 mm) were incubated overnight with monoclonal
mouse anti-TH (1:200; Sigma) or monoclonal mouse anti-NeuN
(1:100; Millipore, Billerica, MA) antibodies and then for 1 h with
secondary biotin-coupled anti-mouse antibodies (1:200; Vector
Laboratories, Burlingame, CA). 3,3-Diaminobenzidine tetrachlo-
ride (Sigma) was used for detection.
Double fluorescence immunostaining was performed by incu-
bating the sections overnight with monoclonal anti-TH antibodies
(mouse; 1:50; Sigma; code: T1299) and polyclonal antibodies
recognizing D1 receptors (rabbit; 1:20; Santa Cruz, CA; code: sc-
14001), D2 receptors (goat; 1:20; Santa Cruz; code: sc-7522), D4
receptors (rabbit; 1:20; Chemicon, Tecumela, CA; code:
AB1787P), choline acetyltransferase (ChAT) (goat; 1:100; Milli-
pore; code: AB144P), glutamic acid decarboxylase (GAD) (rabbit;
1:100; recognizing both GAD65 and GAD67; Sigma; code:
G5163), the high affinity dopamine transporter (DAT) (rat; 1:50;
Millipore; code: MAB369), Aromatic L-amino acid decarboxylase
(AADC) (rabbit; 1:100; Enzo Life Sciences, Farmingdale, New
York; code: BML-AZ1030), Leu-Enkephalin (ENK) (rabbit; 1:50;
Millipore; code: AB502), Dynorphin A (rabbit; 1:100; Abcam;
code: ab11134), Ki67 (rabbit; 1:100; Spring Bioscience Pleasan-
ton, CA; code: M3060) and then for 1 h with secondary
fluorescein-conjugated anti-mouse antibodies (1:100; Vector) and
Cy3-conjugated anti-rabbit, anti-goat or anti-rat antibodies (1:500;
Chemicon). Before incubation with primary antibodies, sections
were treated with 10 mM, pH 9.0, Tris-EDTA buffer, and heated
in a microwave for 10 min for antigen retrieval.
Double fluorescence immunostaining for TH and BrdU was
performed by incubating the sections with a polyclonal anti-TH
antibody (rabbit; 1:200; Sigma; code: SAB2103892) and a
monoclonal anti-BrdU antibody (mouse; 1:10; BD Biosciences,
San Jose, CA; code: 347580). For an optimal BrdU immunostain-
ing, sections were incubated in 1 N HCl for 60 min at room
temperature and then with 0.1 M sodium tetraborate for 10 min.
After overnight incubation with anti-BrdU antibody, sections were
incubated with secondary fluorescein-conjugated anti-mouse
(1:100; Vector) for 1 h. After an extensive washing, section were
incubated overnight with anti-TH antibody and then with
secondary Cy3-conjugated anti-rabbit antibodies (1:100; Vector)
for 1 h at room temperature. Before incubation with primary
antibodies, sections were incubated in citrate buffer (10 mM,
pH 6.0) or in Tris-EDTA buffer (10 mM, pH 9.0) and heated in a
microwave for 10 min for BrdU or TH antigen retrieval,
respectively.
Co-localization of proteins was examined by densitometric
analysis of green and red fluoresce in selected microscopic regions.
The specificity of the antibodies used for immunohistochemical
analysis of D1 and D2 dopamine receptors was performed using
striatal tissues coming from D1 and D2 knockout mice (Figure 6B).
Tissue sections (10 mm) were incubated overnight with poly-
clonal antibodies recognizing D1 receptors (rabbit; 1:20; Santa
Cruz, CA) or D2 receptors (goat; 1:20; Santa Cruz) and then for
1 h with secondary biotin-coupled anti-rabbit (1:200, Vector
Laboratories) or anti-goat antibodies (1:500; Vector Laboratories).
3,3-Diaminobenzidine tetrachloride (Sigma) was used for detec-
tion.
Cluster analysis
We measured the regional distribution of TH+ striatal cells with
respect to TH+ fiber clusters by tracing a calibrated straight line
connecting each TH+ striatal cell and the nearest cluster of fibers.
We traced three segments connecting the cell body of TH+ cells to
the central border and to the inferior and superior border of the
clusters (see image in Fig. 2A), respectively, and we calculated the
mean length of the three segments for each determination.
Stereological cell counting
The number of TH+ cells in the striatum was assessed by
stereological technique and an optical fractionator using a Zeiss
Axio Imager M1 microscope equipped with a motorized stage and
focus control system (Zeta axis), and with a digital video camera.
The software Image-Pro Plus 6.2 for Windows (Media Cybernet-
ics, Inc., Bethesda, MD) equipped with a Macro was used for the
analysis of digital images. The Macro was obtained by Immagine
and Computer, Bareggio, Italy and the characteristics of this
Macro are published [39]. The analysis was performed on 6
sections of 30 mm, sampled every 300 mm on the horizontal plan
of the striatum, in which the striatum was identified and outlined
at 2.56magnification. TH+ or NeuN+ cells were counted at 1006
magnification as described [40]. For stereological analysis, we used
a grid of disectors (counting frame of 100675 mm; grid size
3006300 mm), with 1.3 as numerical aperture of the lens. The
striatum volume, calculated according the Cavalieri method, was
260.5 mm3 for each striatum as assessed in six sections of 30 mm
cut every 300 mm on the horizontal plan of the striatum.
The total number of TH+ cells per hemistriatum was computed
from the formula: N=S(n)61/SSF61/ASF61/TSF, where n is
the total number of cells counted on each disector; SSF (fraction of
sections sampled) the number of regularly spaced sections used for
counts divided by the total number of sections across the striatum
( = 1/6); ASF (area sampling frequency) the disector area divided
by the area between disectors (7500 mm26disector number/region
area); and TSF (thickness sampling frequency) the disector
thickness divided by the section thickness (20 mm/30 mm).
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